| Document |
Document Title |
|
WO/2019/166992A3 |
A method may include collecting a sample of soil via a soil collection unit. Additionally, the method may include mixing the soil with a liquid to form a colorless solution. Further, the method may include dividing the colorless solution...
|
|
WO/2019/198094A1 |
Embodiments of the present disclosure relate to a method and a system for estimating Total Count (TC) of blood cells in a blood smear. A blood analyzer receives a plurality of images of the blood smear captured from a monolayer. One or m...
|
|
WO/2019/197202A1 |
Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of three bio marker proteins...
|
|
WO/2019/199865A1 |
The present disclosure relates to digital immunoassays performed on diluted samples obtained from dried blood spots, for example dried capillary blood samples, to detect the presence or absence of a physiological condition by quantifying...
|
|
WO/2019/199910A1 |
Methods and compositions for detecting and quantifying cytokines are provided. The disclosed assays have reduced assay interference relative to commercially available assays and/or a control assay. The interference can be cytokine depend...
|
|
WO/2019/200245A1 |
The disclosure provides methods and compositions for determining the kinase activity profile of a biological sample, e.g., that contains multiple kinases.
|
|
WO/2019/197974A1 |
Antibodies that recognize and attach to human telomerase reverse transcriptase (hTERT) peptides presented by tumor cells are provided. These antibodies are useful in detection and isolation of circulating tumor cells (CTCs), in diagnosin...
|
|
WO/2019/200256A1 |
Provided herein are methods for treating cancer, comprising administering to a subject having cancer a therapeutically effective amount of a CD73 antagonistic antibody alone or in combination with a PD-1/PD-L1 axis antagonist antibody.
|
|
WO/2019/200325A1 |
The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of ...
|
|
WO/2019/200300A1 |
A processing platform in one embodiment comprises one or more processing devices each including at least one processor coupled to a memory. The processing platform is configured to implement a crosslink identification and validation algo...
|
|
WO/2019/200357A1 |
The present disclosure relates to agents that bind CD47 and comprise an Fc domain, and methods of identifying patients likely to respond to said agents. The disclosure also relates to methods for treating or ameliorating one or more symp...
|
|
WO/2019/199945A1 |
Provided herein are methods compositions and methods to generate pMHC libraries, and methods of using the pMHC libraries to determine the sequences of T cell receptors, and T cell developmental and activation status.
|
|
WO/2019/197836A1 |
The invention relates to Clostridioides difficile, and in particular to compounds, polypeptides and mixtures for the treatment of C. difficile infections. The invention also relates to nucleic acids, vectors comprising these nucleic acid...
|
|
WO/2019/200403A2 |
Predicting the likelihood of lung disease in a subject, comprising labeling an ex-vivo sputum sample from a subject with one or more of the following: a first labeled probe that binds a biomarker expressed on a white blood cell populatio...
|
|
WO/2019/196194A1 |
A kit for detecting a human regulatory T cell subtype and a detection method thereof, belonging to the technical field of cell subtype detection. The kit comprises the following components: a blood diluent, a mononuclear cell separation ...
|
|
WO/2019/198648A1 |
A model composition of body odor that comprises at least one sulfur compound selected from between allyl mercaptan and dimethyl trisulfide.
|
|
WO/2019/197988A1 |
Compositions and methods are provided for blocking Tim4 on the surface of myeloid cells in order to treat and prevent cancer in a subject. Blocking Tim4 on the surface of myeloid cells can restore anti-tumor immunity and reduce the uptak...
|
|
WO/2019/195942A1 |
A method for increasing gastric tract acid (GTA) production in a mammalian subject. The method comprises administering a therapeutically-effective amount of a composition comprising at least one live or attenuated culture of a microbial ...
|
|
WO/2019/200326A1 |
Kits, compositions, and methods for labeling target materials or target analytes are considered. The composition can include one or more affinity molecules indirectly conjugated to one or more detection moieties. The kit can be used to d...
|
|
WO/2018/183448A8 |
A method for determining in a sample, by mass spectrometry, the presence, absence or amount of one or more lipid species from one or more lipid classes is described herein. The one or more lipid classes are selected from the group consis...
|
|
WO/2019/199499A1 |
The present disclosure relates to methods, systems, and devices for performing analyses of biological nanoparticles. More specifically, the present disclosure relates to methods, systems, and devices for performing single biological nano...
|
|
WO/2019/200030A1 |
Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a ...
|
|
WO/2019/200243A1 |
Methods for treating cancer by administration of two or more therapeutic agents are provided. The two or more therapeutic agents include a cyclin-dependent kinase inhibitor (e.g., alvocidib) and an anthracycline (e.g., daunorubicin or id...
|
|
WO/2019/155366A3 |
The subject of the present invention is the sensor for the impedance measurements of the biological or chemical factor sample in the potentiostat system comprising the reference electrode RE and counting electrode CE with the electric co...
|
|
WO/2019/200177A1 |
Methods for detecting colorectal cancer or precancerous conditions such as adenomatous polyps in a subject by detection of a galactose-containing 40-kDa molecule in a serum sample from the subject are provided. Methods for quantifying th...
|
|
WO/2019/195878A1 |
Provided herein are methods for preparing a phosphorylated protein for phosphoproteomic analysis. Methods for preparing a phosphorylated protein for phosphopeptide analysis using mass spectrometry (MS) are described. Kits for preparing a...
|
|
WO/2019/106427A3 |
The present invention relates to a method of HIV- 1 latency reversing agents (LRA). The method comprises the steps of (a) culturing in vitro a fraction of CD4+ T cells obtained from a HIV-infected subject with at least one latency revers...
|
|
WO/2019/200395A1 |
An example method for quantitatively predicting a cancer patient's response to immune-based or targeted therapy is described herein. The method can include receiving patient data for the cancer patient. The patient data is derived from a...
|
|
WO/2019/199041A1 |
A device for measuring a moisture content in soil according to an aspect of the present invention comprises: a conductive wire structure which can be inserted into soil, includes a first and a second conductive wire, and is formed to hav...
|
|
WO/2019/196989A1 |
The invention relates to a device (1) for detecting a foreign body (2, 3) in a measuring space (4), in a transported substrate flow of a foodstuff or an animal foodstuff, the measuring space (4) being a throughflow body (5) in the form o...
|
|
WO/2019/197449A1 |
Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of two biomarker proteins. A...
|
|
WO/2019/199733A1 |
Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of inhibitors of ARlnc1 for treating cancer.
|
|
WO/2019/197890A1 |
The present disclosure relates to a method and system for determining Total Count (TC) of RBCs in a Peripheral Blood Smear (PBS). The system receives a plurality of images from the monolayer of the PBS. Further, the system extracts, segm...
|
|
WO/2019/173503A3 |
Anti-AS-SPIK antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to diagnose disorders characterized by the expression of ...
|
|
WO/2019/200307A1 |
Analyzing samples injected into an inductively coupled plasma source can be improved by one or more of a stabilizing solution mixable with a sample prior to injection and a heated injector. The stabilizing solution can minimize the diffe...
|
|
WO/2019/199089A1 |
The present invention relates to a method for screening a material reversing fine dust-induced restriction of keratinocyte differentiation, the method comprising a step of identifying a relative degree of formation of primary cilia in ke...
|
|
WO/2019/101812A3 |
The present invention relates to a method for identifying a compound that binds, suppresses, blocks, inhibits, and/or modulates the activity of an olfactory receptor that is activated by a laundry malodor causing substance, a moldy malod...
|
|
WO/2019/200288A1 |
Described herein are assays and methods to detect and/or treat a non-responsive or treatment resistant p16 positive tumor in a subject in need thereof. The disclosed method can also involve determining if the subject is HPV positive or n...
|
|
WO/2019/199871A1 |
The present disclosure relates to immunoassays for NF-L performed on liquid samples derived from physiological fluids such as venous blood to detect the presence or absence of a physiological condition by quantifying one or a combination...
|
|
WO/2019/197401A1 |
Embodiments of the present technology may allow for improved and more reliable tunneling junctions and methods of fabricating the tunneling junctions. Electrical shorting issues may be reduced by depositing electrodes without a sharp sid...
|
|
WO/2019/197543A2 |
Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the c...
|
|
WO/2019/160739A3 |
Provided herein are methods and systems for biochemical analysis, including compositions and methods for processing and analysis of small cell populations and biological samples (e.g., a robotically controlled chip-based nanodroplet plat...
|
|
WO/2019/200342A1 |
The present disclosure provides methods of treating Alzheimer's Disease (AD) and rescuing cognitive deficits associated with AD in a subject having an apoE4/4 genotype, by administering a therapeutically effective amount of the loop-diur...
|
|
WO/2019/197642A1 |
Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the c...
|
|
WO/2019/197819A1 |
The present invention relates to engineered a cytolytic immune cell comprising: i) a releasable protein which comprises a polypeptide of interest (POI) and a first interaction domain; and ii) a retention protein which is retained within ...
|
|
WO/2019/199842A2 |
Blood and bodily fluid reader systems, including circulating biomarkers involving multiple mitochondrial releasates for providing real-time, at-the-scene objective indicia of individuals sustaining mild TBI. As a therapeutic component fo...
|
|
WO/2019/197200A1 |
Disclosed is an in vitro method for assessing or predicting the response of a human patient to treatment of periodontal disease. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva of a ...
|
|
WO/2019/195889A1 |
The present invention relates generally to a method of identifying a subject at risk of recurrence of breast cancer following ablation of a breast cancer tumour, the method comprising: (i) obtaining a sample of breast cancer cells from a...
|
|
WO/2019/200223A1 |
The present invention relates, in part, to certain serum biomarkers and use thereof in methods for treating cancer, such as in evaluating and/or in additional methods such as predicting patient responses to treatment with a CXCR4 inhibit...
|
|
WO/2019/196554A1 |
A blood-activated clotting time assay biosensor and a manufacturing method thereof. The blood-activated clotting time assay biosensor (10) comprises a bottom layer (300), an intermediate layer (200) and a top layer (100), which are stack...
|
